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Abstract: Delivering a drug to the target site with minimal-to-no off-target cytotoxicity is the major
determinant for the success of disease therapy. While the therapeutic efficacy and cytotoxicity of the
drug play the main roles, the use of a suitable drug delivery system (DDS) is important to protect the
drug along the administration route and release it at the desired target site. Polysaccharides have been
extensively studied as a biomaterial for DDS development due to their high biocompatibility. More
usefully, polysaccharides can be crosslinked with various molecules such as micro/nanoparticles
and hydrogels to form a modified DDS. According to IUPAC, hydrogel is defined as the structure
and processing of sols, gels, networks and inorganic–organic hybrids. This 3D network which often
consists of a hydrophilic polymer can drastically improve the physical and chemical properties of
DDS to increase the biodegradability and bioavailability of the carrier drugs. The advancement of
nanotechnology also allows the construction of hydrogel DDS with enhanced functionalities such
as stimuli-responsiveness, target specificity, sustained drug release, and therapeutic efficacy. This
review provides a current update on the use of hydrogel DDS derived from polysaccharide-based
materials in delivering various therapeutic molecules and drugs. We also highlighted the factors that
affect the efficacy of these DDS and the current challenges of developing them for clinical use.
Keywords: hydrogel; polysaccharides; drug; delivery systems; nanoparticles
1. Introduction
Drug delivery is defined as the process of administering a pharmaceutical compound
to achieve the targeted transport and release to specific therapeutic sites in humans and
animals via various routes of administration, including oral, transmucosal, topical, inhala-
tion, and intravenous routes. Although drug delivery has a long history dating back to
when humans first ingested herbal remedies, most of the notable technological advances
only began to take place in the 1970s. Since then, the advancement has not only focused on
the targeted delivery of drugs, but also on maintaining a controlled release rate, achieving
greater cellular uptake, and reducing the non-specific effects, all of which often require the
drug to have a high shelf-life and stability [1–4]. To this end, the modern drug delivery
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systems (DDSs) play a crucial role in ensuring the above criteria are met. Among the DDSs,
a polysaccharide-derived system has drawn considerable attention due to its numerous
attractive characteristics [5].
Polysaccharides are carbohydrates consisting of repeating monosaccharide units
linked by glycoside bonds. Polysaccharides can be isolated from cheap natural resources,
such as algae (e.g., alginate), plants (e.g., starch, cellulose, and pectin), animals (e.g.,
chitosan, hyaluronic acid, and chondroitin), and microorganisms (e.g., pullulan, xanthan
gum, and dextran) [6–8]. These polymers possess a wide range of physical, chemical, and
biological properties which contribute to their high biocompatibility and bioactivity, and
low enzymatic degradability. In addition, the presence of freely available functional groups
such as carboxyl, amino, hydroxyl, and other hydrophilic groups allow drug conjugation
and a series of chemical modifications which suit the desired applications [9,10]. However,
limitations of DDS derived from natural polysaccharides compared to synthetic polymers
such as polylactic acid (PLA), polylactic-co-glycolic acid (PLGA), and polyethylene glycol
(PEG), have been recognized over the years [11]. These drawbacks include inconsistent
properties due to different sources, uncontrolled uptake of water, low mechanical strength,
and uncertain degradation patterns [9]. This has given rise to the development of DDSs
using polysaccharide derivatives such as carboxymethylcellulose (CMC), as well as the
subsequent formation of nanoparticle (NP)-based and hydrogel-based DDSs to overcome
the abovementioned issues [12,13].
Over the years, micro- and nano-particulate DDS have gained interest owing to
their unique characteristics such as a higher cell-penetrating capacity, target specificity,
suitability for various types of administration routes, rich surface chemistry, and high
flexibility in chemical modifications [14]. Examples of these DDS include microspheres and
microcapsules. Microspheres are monolithic microparticles with a spherical shape, while
microcapsules are microparticles with a core surrounded by other substances [15]. As the
reduced size of DDS could contribute to the improved delivery of therapeutic molecules,
the NP DDS have been introduced with added features of stimuli-responsiveness and
sustained release [16]. On the other hand, hydrogel-based DDSs, which are mostly derived
from polysaccharides, are also used as a popular vehicle due to their high biocompatibility,
high biodegradation, and low immunogenicity [17]. Due to the advantages of NPs and
hydrogel DDSs, both have been combined to generate various types and sizes of NP-
hydrogel DDSs such as macrogels, microgels, and nanogels to maximize the therapeutic
efficacy of DDSs [18].
In this review, we provide updates on the utilization of polysaccharides for hydrogel-
based DDS construction. We discuss different types of therapeutic molecules delivered by
these DDSs from recent studies and highlight the factors that could affect the efficacy of
these DDSs, as well as the challenges in their development for clinical use.
2. Hydrogel-Based Drug Delivery Systems
The use of polysaccharides for the development of hydrogels became an area of in-
terest due to their high biocompatibility and biodegradability. Other advantages include
accessibility, cost-efficiency, and ease of surface modification through chemical means.
Polysaccharides-based hydrogels are based on chitosan, starch, cellulose, pectin, alginate,
psyllium husk, hyaluronic acid, guar gum, and their derivatives. Physical and chemi-
cal methods are used to crosslink the natural polymers to form beads, films, and disks.
Chemicals crosslinkers (glutaraldehyde, epichlorohydrin, tripolyphosphate, and 1-ethyl-3-
(3-dimethylaminopropyl)carbodiimide (EDC), and radiation, such as gamma and electron
beams) are used to crosslink these natural polymers [19]. The drug carriers formulated
from natural polymers are considered an ideal material to ensure the safety of patients due
to their colonic enzymatic degradation into harmless by-products that are easily excreted
from the body.
Hydrogels are three-dimensional (3D) crosslinked polymer networks with a high
swelling due to the presence of hydrophilic groups (e.g., -OH, -CONH−, and -SO3H). Hy-
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drogels possess tunable physicochemical properties, low immunogenicity, ease of function-
alization, and biocompatibility [20]. Polysaccharide-based hydrogels are highly desirable
as they are intrinsically biodegradable and renewable, as well as abundant in nature [21].
Moreover, hydrogels can be engineered to encapsulate various therapeutic materials (e.g.,
small-molecule drugs, hydrophobic and hydrophilic drugs, growth factors, and inhibitors)
and to protect labile drugs against degradation. The further development of hydrogels
by incorporating nanomaterials (e.g., NPs, nanowires, nanotubes, and nanosheets) for the
formation of hydrogel nanocomposites can be advantageous for DDSs, contributing to the
increase of antibacterial activity, mechanical stability, and magnetic properties [18].
Hydrogel-based drug carriers differ in size (e.g., macrogels, microgels, and nanogels),
architecture, and physical/chemical functions that dictate the release of drugs for tar-
geted DDS. Macroscopic hydrogels (i.e., in situ-forming, microporous, and shear-thinning
hydrogels) are suitable for transepithelial administration or injection, whereas hydrogel-
forming microneedles have been widely used for transdermal drug delivery. Microgels
are micrometer-sized hydrogel particulates that have shown promising potential for oral
and pulmonary drug delivery. On the other hand, nanogels (10 to 100 nm) are suitable
for systemic delivery. Hydrogels are attractive due to their ‘soft’ properties and high
water content which are achieved either via physical or chemical crosslinking methods and
allow them to be used for non-invasive delivery through injection. Physical crosslinking
occurs via non-covalent interactions such as hydrogen bonding, hydrophobic–hydrophilic
interactions, and ionic interactions. Typically, the physically crosslinked hydrogels man-
ifest reversible sol-gel characteristics; rendering them sensitive to various factors such
as polymer composition, temperature, ionic strength, and crosslinking initiators [22,23].
Although the preparative conditions for physical gelation are usually mild and avoid
toxic reagents, hydrogels typically have poor mechanical properties. Therefore, physi-
cally crosslinked hydrogels would likely have a low stability in the harsh environment of
body blood circulation [24]. Chemical crosslinking prevents the dissolution of polymer
chains in aqueous media resulting in better gel stability compared to physically crosslinked
hydrogels. The formation of covalent linkages between the polymeric chains increases
the stability and integrity of the crosslinked networks. Typically, chemically crosslinked
hydrogels are synthesized through the crosslinking of labile functional groups such as ester,
carbonate, amide, anhydride, and phosphazene [23,24]. One of the common reactions is
the Schiff-base reaction which forms imine bonds that are stable at physiological pH but
labile at acidic pH [24]. Interestingly, both crosslinking strategies are tunable to fabricate
smart hydrogels with functionalities (e.g., targeting ligands) that respond to physiological
or extrinsic stimuli to trigger drug release. This section discusses the characteristics and
functions of hydrogels at different sizes (i.e., macrogels, and microgels/nanogels), and the
development of novel hydrogel-forming microneedles and stimuli-responsive hydrogels.
2.1. Macrogels
2.1.1. In Situ-Forming Hydrogels
In situ-forming hydrogels offer easy administration via minimally invasive injection
and the accurate dose delivery of therapeutic drugs in a controllable manner. The syn-
thesis of in situ-forming hydrogels is categorized as non-covalent, due to temperature,
pH, ionic, and self-assembly; and covalent, due to crosslinking light or chemical/enzyme
precursors [25]. Non-covalent crosslinking induces the formation of secondary bonds
(e.g., hydrogen bonding, and electrostatic and hydrophobic interactions), triggering the
polysaccharides to undergo a sol-gel transition into semi-solid hydrogels via in situ gelling
systems that respond to physiological stimuli (e.g., change of physiological pH, body
temperature, and biological fluid’s ionic strength). This approach is ideal for the delivery
of small-molecules and sensitive drugs, as it avoids using harmful chemical agents [26].
Yin and colleagues developed thermo-responsive in situ-forming hydrogels via physical
crosslinking with a rapid gelation time of 15 s initiated closer to body temperature. The
drug-loaded hydrogels show the sustained release of NPs co-loaded with indomethacin
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(IND) and methotrexate (MTX) over 72 h for the treatment of rheumatoid arthritis [27].
In this instance, the gelation rate of physical crosslinking is influenced by polymer and
drug compositions, as well as collective physiological responses. The delayed gelation in
physiological environments may cause a burst-out effect due to prolonged exposure in
tissue exudates, causing rapid clearance and reducing drug bioavailability. The fabrication
of in situ hydrogels using the chemical crosslinking method enhances the mechanical prop-
erties of hydrogels. This method utilizes chemical crosslinkers (e.g., genipin, formaldehyde,
glutaraldehyde, and epoxy compounds) to react with crosslinkable functional groups of
the polysaccharides [28,29]. For instance, the primary amino groups (-NH2) of chitosan
and gelatin were co-crosslinked by β-glycerophosphate and genipin forming in situ hy-
drogels for intraocular drug delivery [29]. Recently, ‘click’ reactions such as Diels-Alder
and thiol-ene reactions showed promising potential to produce in situ-forming hydrogels
under mild preparative conditions [28,30].
2.1.2. Macroporous Hydrogels
Macroporous hydrogels have been widely used to deliver therapeutic drugs, genes,
or cells. In regenerative medicine (e.g., tissue engineering and wound healing), macrop-
orous hydrogels can be ideal bio-hydrogels that protect cells and other bioactive materials
against stresses during implantation and later promote cellular integration into the host
tissues. The large and interconnected macropores enhance gaseous and nutrient exchanges
to support cell infiltration and growth, thereby accelerating healthy tissue regeneration.
In addition, macroporous hydrogels can load a very high amount of bioactive materials
(e.g., drugs, growth factors, cytokines, and nanoparticles, etc.) attributed to their high
porosity. Inevitably, these macropores are essential to fabricate effective drug carriers for
targeted and localized delivery [31]. Cryogelation, particulate leaching, lyophilization, gas
foaming, additive manufacturing (3D printing), freeze-thawing, and microgel assembly
methods have been used to fabricate macroporous hydrogels. These techniques generally
avoid harmful chemical agents or high temperatures, making macroporous hydrogels
ideal to mimic the extracellular matrix (ECM) of native tissues [32,33]. Most recently,
lyophilized macroporous D-galactose-based hydrogels exhibited a pore size ranging from
4 to 20 µm and the sustained release of gentamicin (hydrophilic drug) up to 92% within
72 h [34]. Although injectable drug-loaded hydrogels can be administered using non-
invasive methods, they possess poor mechanical stability and lack porosity to efficiently
entrap therapeutic materials, hence compromising their continued clinical use. Meanwhile,
macroporous hydrogels exhibit excellent mechanical properties, porosity and interconnec-
tivity permitting better control over the encapsulation and release of therapeutic mate-
rials [35,36]. Ideally, injectable macroporous hydrogels would possess macropores with
sizes ranging from 50 to 300 µm to facilitate various cell adhesion and migration, including
mammalian cells [37]. Combining the advantages of both injectable and macroposity
properties would increase the drug carrier’s potential as a DDS. For example, fabrication of
gelatin-based injectable macroporous hydrogels via the microgel assembly method resulted
in higher cellular infiltration and the controlled release of platelet-derived growth factors,
which enhanced cell proliferation [36].
2.1.3. Shear-Thinning Hydrogels
Hydrogels with shear-thinning properties undergo reversible gel-sol transition upon
the application of shear stress. Interestingly, shear-thinning properties allow for the ho-
mogeneous encapsulation of drug payloads and smooth injection without the clogging of
the injection needle by hydrogels returning to their original viscosity and shape once the
mechanical load (shear stress) is removed [38]. Shear-thinning hydrogels are increasingly
used in DDSs owing to their ability to conform to the shape of the injection cavity, thus
maximizing contact with the targeted tissues/organs for localized drug delivery. Recently,
Prasad et al. studied the shear-thinning properties of their hydrogels which migrated along
constricted microchannels mimicking human microcapillaries. In their study, the hydrogels
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deformed and retained their original shape upon the cessation of a high shear, expressing
both shear-thinning and self-healing properties, as illustrated in Figure 1. Furthermore,
the hydrogels exhibited a longer retention of doxorubicin during migration with sustained
drug release [39]. In this case, both shear-thinning and self-healing properties offer many
advantages, including enhanced mechanical properties and reduced embolization risk
in the systemic circulation compared to their counterpart, in situ-forming hydrogels [38].
Additionally, Gharaie et al. reported smart shear-thinning hydrogels with pH-responsive
characteristics. They found that the hydrogels showed a significant swelling rate at pH
9.18, followed by high drug release presenting a sustained release characteristic ideal for
treating wounds [40].
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2.2. icrogels and anogels
2.2.1. Synthesis and Characteristics of Microgels and Nanogels
The particulates of hydrogels on the size scale ranging from 10 nm to 5 µm, known as
microgels or nanogels, are of growing interest for the delivery of specific therapeutic drugs
to specific sites in the body [41]. In general, microgels less than 5 µm in diameter are suitable
for oral and pulmonary delivery, while nanogels with a 10–100 nm diameter can be used for
systemic drug administration. The advantages of microgels/nanogels for polymer-based
DDSs include the stability of the interior network structure, a rapid response time, a large
surface area for multivalent bioconjugation, and a high ability to retain water and bioactive
drugs within their 3D network structure [42]. According to Oh et al., synthetic nanogels
are primarily synthesized by the heterogeneous polymerization of hydrocarbon-based
hydrophilic or water-soluble monomers in the presence of multifunctional crosslinkers [43].
Microgels/nanogels are formed by physically or chemically crosslinked polymer
chains in micro- or nano-scale size (Figure 2). For physical crosslinking, this usually occurs
through non-covalent attractive forces, including hydrophilic–hydrophilic, hydrophobic–
hydrophobic, and ionic interactions, and/or hydrogen bonding. The properties of the
polymer highly depend on several factors, such as polymer composition, temperature,
ionic strength, and the crosslinking agent used [44]. For example, Nakai et al. synthesized
a physically crosslinked nanogel based on the self-assembly of cholesteryl-group-bearing
hyaluronic acid. In this study, injectable hydrogel was formed by the salt-induced asso-
ciation of the hydrogel [45]. In another study, poly(N-tert-butyl acrylamide) side chains
were grafted on the methylcellulose backbone to form self-assembling nanogels through
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hydrophobic interactions. The nanogels released the entrapped dexamethasone slowly
over several weeks, which showed its potential for ocular drug delivery [46]. Recently,
Zhou et al. described the preparation of the self-assembled sodium alginate-chitosan
nanogel, based on the interaction of the positive charge of carboxymethyl chitosan and the
negative charge of sodium alginate [47]. Although the preparative conditions for physical
gelation are usually mild and avoid the use of toxic reagents, the gels typically have poor
mechanical properties that eventually cause low stability in the harsh environment in body
blood circulation [24].




Figure 2. Examples of microgels/nanogels crosslinking mechanisms. (a) carboxymethylcellu-
lose(CMC)-branched poly(ethyleneimine)(bPEI) nanogels obtained via ionic interaction and (b) 
formation of dextran microgels via Schiff-base reaction as pH-responsive drug vehicles. 
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sized a microgel by crosslinking chitosan and gelatin with succinimide-end PEG, which 
exhibited a sustained release of folic acid within 72 h, at physiological pH and temperature 
[48]. Furthermore, no significant change in the dimension of the microgels was observed 
for 7 days, indicating the stability of the microgels [48]. To make the chemically cross-
linked hydrogels biodegradable, crosslinks with labile bonds such as ester, carbonate, am-
ide, anhydride, and phosphazene are usually introduced [49]. In a study by Su et al., mi-
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increase the stability and integrity of the structures. For instance, Wang et al. synthesized a
microgel by crosslinking chitosan and gelatin with succinimide-end PEG, which exhibited
a sustained release of folic acid within 72 h, at physiological pH and temperature [48].
Furthermore, no significant change in the dimension of the microgels was observed for
7 days, indicating the stability of the microgels [48]. To make the chemically crosslinked
hydrogels biodegradable, crosslinks with labile bonds such as ester, carbonate, amide,
anhydride, and phosphazene are usually introduced [49]. In a study by Su et al., microgels
were formed via Schiff-base linkages between aldehyde dextran and ethylenediamine in a
water-in-oil microemulsion, as shown in Figure 2b [50]. As the Schiff bases linkages are
hydrolyzable and less stable at an acidic pH, the microgels exhibited a unique hydrolysis
profile in tumors [50]. In another study, carboxymethyl starch microgels with various
crosslinking densities were synthesized using sodium trimetaphosphate. The microgels
were reported as viscoelastic solids when the storage modulus was higher than the loss
modulus over the frequency range of dispersions with the polymer at concentrations of 3%
(w/w) at 25 ◦C [51].
2.2.2. Use of Microgels or Nanogels as Drug Delivery Systems
The application of nanogels in DDSs is highly advantageous, owing to the stable
interior 3D networks for higher drug payloads, rapid response times, and larger surface
area for multivalent bioconjugation. Microgels are favorable for oral and pulmonary drug
delivery as these particulates can avoid fast renal clearance, sequestering by the spleen,
and the phagocytosis by macrophages [52]. In a previous study, the aerodynamic size
of the nanoparticle-inside-microgel (nano-in-microgel) system allowed deep pulmonary
drug delivery while preventing the rapid clearance by alveolar macrophages. The micro-
gel underwent enzymatic degradation releasing therapeutic nanoparticles to treat acute
and chronic pulmonary diseases such as asthma, cystic fibrosis and chronic obstructive
pulmonary disorder [52]. Owing to the size of nanogels, drug-loaded nanogels could
easily reach the smallest capillary vessels and penetrate tissues either through paracellular
or transcellular routes. Moreover, nanogels could enhance the pharmacological effect
of small-molecule drug and a stability against chemical or enzymatic degradations [52].
The fabrication of nanogels using advanced technologies such as microfluidic-assisted
methods allows for the controlled and large-scale production of nanogels [53]. Nanogels
with a narrow size distribution are fabricated by controlling microfluidic conditions such
as chip design, rheological properties, and tuning of the flow rate. The robust fabrication
strategy enables high control over the nanogel’s properties (e.g., size, surface changes,
and polydispersity), payload delivery and release mechanism [53]. In one study, alginate
nanogels were fabricated using the microfluidic method. It was found that the uniform
and monodisperse nanogels can be tuned by adjusting the flow rate ratio, thus controlling
the release profile of payloads and avoiding premature (burst) release [53].
Over the years, polysaccharides-based microgels/nanogels have attracted consider-
able attention in drug delivery applications as they are intrinsically biodegradable and
renewable, as well as abundant in nature. It is known that hydrogels between 0.5–10 µm
can be phagocytized by macrophages, while hydrogels smaller than 10 nm can be efficiently
removed by the kidney [54,55]. As microgels/nanogels derived from polysaccharides are
hydrophilic in nature, they have been widely studied as the drug carriers for hydrophilic
drugs. Recently, layer-by-layer (LBL) polyelectrolyte-coated alginate microgels were synthe-
sized for the DDS. The LBL deposits of poly(allylamine)/poly(sodium 4-styrenesulfonate)
(PAH/PSS) on alginate microgels acted as a diffusion barrier for sustaining the release of
minimal hydrophilic drugs. The barrier mechanism worked by increasing the diffusion
pathway and molecular interaction potential between drug molecules and the bilayers.
The study reported that the novel microgels successfully sustained the release of sodium
benzoate and zosteric acid for up to 72 and 120 h, respectively [56]. Yurkshtovich et al.
demonstrated the ability of starch phosphate microgels to encapsulate interferon-alpha
2b and aimed to deliver the therapeutic agent for cancer or viral infection treatments [57].
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Furthermore, Zhang et al. developed the self-stabilized hyaluronic acid nanogels for
the codelivery of doxorubicin and cisplatin to treat osteosarcoma. Cisplatin acted as the
crosslinker and ancillary anti-carcinogen. As a result, the premature release of doxorubicin
was avoided, and a synergistic anti-tumor effect was achieved [58].
Interestingly, microgels/nanogels can be promising candidates for delivering poorly
soluble drugs, given that the polymer structures are appropriately engineered [59]. For
example, Sawada et al. developed a new self-assembled natural polysaccharide nanogels
using xyloglucan (XG) [60]. The reaction between XG and cholesterol N-(6-isocyanatohexyl)
carbamate resulted in cholesterol-bearing XG (CHXG) molecules. These molecules self-
assembled in water due to the association of the introduced cholesteryl group to form
nanogels with a diameter of 100 nm. They also reported that CHXG nanogels could
be complexed with paclitaxel yet remained in the nanosized range, demonstrating the
CHXG nanogels’ potential as drug carriers. In another study, MTX was conjugated with
chondroitin sulfate (CS), forming a self-assembly nanogel for cancer drug delivery. MTX-
CS nanogels are reported to improve drug solubility, enhancing the anti-tumor effect
while lowering the side effects of MTX [61]. Other than modifying the polymer structures,
hybrid nanosystems can also be used. Recently, Fiorica et al. synthesized the hyaluronic
acid/polyaspartamide-based double-network graphene oxide-containing nanogels for
colorectal cancer treatment. The presence of graphene oxide allowed the loading of a large
amount of irinotecan (33.0% w/w) and contributed to the hyperthermic properties of the
nanogels when irradiated with a near-infrared laser beam [62]. A chitosan containing
magnetite nanogels was loaded with an anti-cancer drug, 5-fluorouracil, by encapsulation
and adsorption processes. The drug release from the nanogel was 46% and 100% for
adsorption and encapsulation processes in 6 h, respectively [63].
2.3. Hydrogel-Forming Microneedles
Microneedle technology is an emerging technology enabling transdermal drug deliv-
ery by puncturing micro-sized needles through the stratum corneum (skin barrier). These
microneedle arrays create microscopic pores delivering drugs to skin microcirculation
and achieving systemic delivery through transdermal administration. Hydrogel-forming
microneedles (hydrogel-MNs) swell to form transient microscale delivery channels to
release drugs without leaving polymer residues behind while minimizing skin damage
and bleeding. The drug delivery mechanism involves the swelling of the hydrogel-MNs,
releasing payloads loaded either in the reservoir layer or within the crosslinked polymers
that diffuse into the dermal microcirculation (Figure 3). Notably, hydrogel-MNs show
the promising administration of high-dose drugs (e.g., metformin hydrochloride, doxoru-
bicin, trametinib, rifampicin, isoniazid pyrazinamide, and ethambutol) and controlled
drug release [64–66]. Hydrogel-MNs address several challenges associated with other
drug administration routes (e.g., oral, pulmonary, and parenteral), such as minimizing
gastrointestinal side effects, rapid clearance and increasing patient compliance due to pain-
free administration. Typically, the height of microneedles ranges between 50 to 900 µm,
allowing them to penetrate the dermis layer while being short enough to reach the dermal
nerves and blood vessels located deeper into the dermis layer as illustrated in Figure 3 [64].
Alternatively, hydrogel-MNs can also be used as biosensors collecting biomarkers from
the interstitial skin fluid (ISF). They represent alternative sampling strategies compared to
invasive sampling approaches (e.g., blood draws, skin, and other tissues biopsies), which
can cause patient discomfort and anxiety. In this instance, microneedle technology is highly
demanded as an advanced point-of-care system for frequent monitoring (e.g., blood glucose
level) and diagnostic pathology, including cancer [67,68]. For example, glucose-responsive
hydrogel-MNs served as a blood glucose sensor and self-regulated drug/insulin delivery
governed by the high sensitivity towards elevated glucose concentration. Such multi-
functional hydrogel-MNs can serve as intelligent artificial devices for advanced diabetes
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2.4. Stimuli-Responsive Hydrogels 
The functional groups of polysaccharides can be functionalized to form hydrogels 
that respond to intrinsic or extrinsic stimuli such as pH, ionic strength, temperature, mag-
netic, and electric field, triggering the release of bioactive materials (e.g., hydrophilic, hy-
drophobic and lipophilic drugs). In particular, hydrogels express high sensitivity towards 
changes in temperature and pH. Therefore, these properties have been widely utilized to 
design innovative drug carriers for cancer therapy. These drug-hydrogel systems are sen-
sitive to the high temperature and the acidic pH of tumor microenvironments, causing the 
cleavage of polymer networks/linkages resulting in swelling or degradation, hence releas-
ing drugs in a targeted manner [69,70]. For example, Zhou’s group designed hybrid mi-
crogels releasing multiple drugs upon activation by the special conditions of tumor mi-
croenvironments (i.e., acidic pH, high temperature and elevated glutathione (GSH) level), 
which can be an effective strategy for combination therapy [70]. Like other biomaterial 
particles, microgels and nanogels can provide both passive and active targeting strategies, 
particularly in cancer therapy. In passive targeting, drug-loaded microgels/nanogels with 
a specific size, shape, and enhanced permeation and retention (EPR) affect circulate 
through the bloodstream before reaching and diffusing through the leaky vasculature of 
the targeted tumor. Additionally, functionalized hydrogel particulates with targeting lig-
ands enable the active targeting of overexpressed tumor receptors to induce drug release, 
as illustrated in Figure 4. Such complex drug-hydrogel systems demonstrate a promising 
platform for the non-invasive delivery of accurately dosed drugs. Karzar Jeddi and 
Mahkam demonstrated the pH-responsive behavior of magnetic spherical carbox-
ymethylcellulose-alginate-chitosan nanogels [71]. At simulated conditions of gastric (pH 
1.2), intestinal, (pH 7.4) and cancer cell environment (pH 5.8), the nanogels released ap-
proximately 90% of dexamethasone, especially in simulated cancer cell microenviron-
ments. The drug release reduced significantly at pH 7.4 (26.2%) and pH 1.2 (29.5%), re-
spectively [71]. The stimuli-responsive drug-hydrogel systems proved promising for var-
ious biomedical applications such as in cancer therapy, wound healing, and tissue engi-
neering.  
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2.4. Stimuli-Responsive Hydrogels
The functional groups of polysaccharides can be functionalized to form hydrogels that
respond to intrinsic or extrinsic stimuli such as pH, ionic strength, temperature, magnetic,
and electric field, triggering the release of bioactive materials (e.g., hydrophilic, hydropho-
bic and lipophilic drugs). In particular, hydrogels express high sensitivity towards changes
in temperature and pH. Therefore, these properties have been widely utilized to design
innovative drug carriers for cancer therapy. These drug-hydrogel systems are sensitive to
the high temperature and the acidic pH of tumor microenvironments, causing the cleavage
of polymer networks/linkages resulting in swelling or degradation, hence releasing drugs
in a targeted manner [69,70]. For example, Zhou’s group designed hybrid microgels releas-
ing multiple drugs upon activation by the special conditions of tumor microenvironments
(i.e., acidic pH, high temperature and elevated glutathione (GSH) level), which can be an
effective strategy for combination therapy [70]. Like other biomaterial particles, micro-
gels and nanogels can provide both passive and active targeting strategies, particularly
in cancer therapy. In passive targeting, drug-loaded microgels/nanogels with a specific
size, shape, and enhanced permeation and retention (EPR) affect circulate through the
bloodstream before reaching and diffusing through the leaky vasculature of the targeted
tumor. Additionally, functionalized hydrogel particulates with targeting ligands enable the
active targeting of overexpressed tumor receptors to induce drug release, as illustrated in
Figure 4. Such complex drug-hydrogel systems demonstrate a promising platform for
the non-invasive delivery of accurately dosed drugs. Karzar Jeddi and Mahkam demon-
strated the pH-responsive behavior of magnetic spherical carboxymethylcellulose-alginate-
chitosan nanogels [71]. At simulated conditions of gastric (pH 1.2), intestinal, (pH 7.4) and
cancer cell environment (pH 5.8), the nanogels released approximately 90% of dexametha-
sone, especially in simulated cancer cell microenvironments. The drug release reduced
significantly at pH 7.4 (26.2%) and pH 1.2 (29.5%), respectively [71]. The stimuli-responsive
drug-hydrogel systems proved promising for various biomedical applications such as in
cancer therapy, wound healing, and tissue engineering.
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crogels [74]. In another study, a glycol chitosan-based nanogel was synthesized through 
the chemical grafting of hydrophobic chains onto a hydrophobic backbone to form an am-
phiphilic polymer that was able to self-assemble in an aqueous environment. As folate 
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3. Drugs and Inhibitors Delivered by Hydrogel-Based Delivery Systems
3.1. Delivery of Genetic Materials
Gene that involves the delivery of genetic material uch as antisense
oligodeoxynucleotides (ODN ), plasmid DNA (pDNA), siRNAs (small interfering RNAs),
and microRNAs (miRNAs) has been recognized s a potential method for the treatment
of cancer, neurod g nerative disorders, and viral infections [72,73]. There are various
types of gene delivery system designed for the restorati n of a specific g ne function or
to knock down the expression of a spe ific gene. The applicati ns of non-viral vectors
made of cationic carriers such as lipids, liposomes, and peptides have been studied due to
their more substantial capacity to carry genetic material. Microgels/nanogels h ve also
been studied as non-viral carriers due to their low toxicity and immu ogenicity [73]. For
example, cationic biodegradable dextran microgels have been synthesized by the emul-
sion polymerization and loaded with siRNA. The siRNA-loaded microgels escaped the
exposure of ultraviolet light and/or free radicals, preventing the integrity of siRNA from
being affected. Besides, high siRNA encapsulation efficiency can be obtained based on the
number of cationic groups incorporated in the microgel network. In addition, the release-
time of the encapsulated siRNA can be controlled by varying the crosslink density of the
microgels [74]. In another study, a glycol chitosan-based nanogel was synthesized through
the chemical grafting of hydrophobic chains onto a hydrophobic backbone to form an
amphiphilic polymer that was able to self-assemble in an aqueous environment. As folate
receptors are highly expressed in some tumors, folate was conjugated to glycol chitosan
by PEG. The results showed that the nanogel-bearing folate enhanced the internalization
of the nanogel following the folate receptor-mediated endocytosis. Besides, the nanogels
were shown to complex with siRNA efficiency, showing a potential vehicle for siRNA
delivery [75]. In a study by Yang et al., CMC was complexed with branch-type cationic
poly(ethyleneimine) (bPEI), to form nanogel for the encapsulation of plasmid DNA [76].
Based on the results, the cytotoxicity of bPEI was lowered when it was in complex with
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CMC. The CMC nanogel complexed with bPEI which improved the cellular uptake of
DNA, as well as gene transfection in stem cells [76]. A silane-crosslinked PEI network
and a pH-responsive poly(2-(hexamethyleneimino)ethyl methacrylate) (PC7A) network
was used to make double-network nanogels. It was also found to facilitate the release
of DNA and endosomal escape at low pH [77]. An oral delivery of nucleic acids in a
TAC6 nanogel to the colon was explored, using caveolae-mediated cellular uptake. The
protein inhibitor of activated STAT1 (PIAS1) is a therapeutic target for inflamed bowel
disease as it has the ability to control NF-KB inflammatory signaling. It was shown that
using TAC6-derived nanogel effectively deliver PIAS1 and decrease the inflammation of
the gut in a murine colitis model [78]. Other nanogels used for the delivery of miRNA
delivery include nanobody conjugated DNA strands loaded onto the surface, forming a
nanobody-functionalized nanogel which is used for tumor-targeted miRNA delivery for
anti-tumor treatment. The study showed that using a nanobody-functionalized nanogel
resulted in increased accumulation of miRNA at the tumor site, mediating the anti-tumor
effect [79].
3.2. Delivery of Peptides or Proteins Using Stimuli-Responsive Hydrogels
Proteins and peptides show promising therapeutic potential; however, they often present
limitations such as low stability, low bioavailability, and high immunogenicity [80–82].
Some of these issues can be solved by using hydrogels as the DDS. For example, The-
une et al. reported that the hydrophilic, dendritic polyglycerol in the nanogel was able
to stabilize the particle size as a crosslinker and, with the co-polymerization of poly(N-
isopropylacrylamide) (NIPAM) and poly(N-isopropylmethacrylamide), it was able to
adjust the volume phase transition temperatures to its desired range at the physiological
condition of 34–37 ◦C [80]. This allowed the release of the encapsulated protein when there
was a temperature change within the range [80]. A nisin-loaded antimicrobial dual respon-
sive nanogel, made of poly(L-lactide)-graft-chondroitin sulfate (PLLA-g-CS) was shown
to release and exert potent antibacterial activity depending on the pH and temperature of
release media. This nanogel could be used for the pH- and temperature-sensitive delivery
of proteins or peptides [81]. An embedded polymeric nanogel was found to preserve
the activity of cytochrome c, an activator of cell apoptosis. The nanogels (CytoC/aNGs)
increased the cellular uptake of cytochrome c and improved the intracellular delivery to the
targeted sites to induce apoptosis [82]. In another study, pH and glucose dual-responsive
biodegradable nanogels were constructed and showed the release of the encapsulated
proteins [83]. These nanogels were highly dependent on glucose or pH concentrations,
where low amounts of proteins were released in physiological pH or under healthy blood
glucose level, while the rapid release was seen at lower pH or under diabetic blood glu-
cose level [83]. Massi et al. generated a temperature-sensitive nanogel that responded to
matrix metalloproteinase-7 (MMP-7) and with the addition of N-cyclopropylacrylamide
(NCPAM) into NIPAM-based copolymer, it allowed the encapsulation of protein cargo and
nanogel-crosslinking at slightly elevated temperatures [84].
3.3. Delivery of Drugs
Drugs used in chemotherapy are known to have a poor stability, low bioavailability,
high toxicity, and non-specificity. Many of these issues can be solved using hydrogels as
the DDS [14]. A study by Li et al. demonstrated a better cellular uptake and improved
cytotoxicity in acid-degradable nanogels which released the DOX drug into the multi-
cellular tumor spheroids and inhibited growth compared to non-sensitive nanogels [85].
The acid-degradable nanogels were stable in the physiological environment and could
be degraded in a mildly acidic environment [85]. A study reported that hyaluronic acid
(HA):sucrose nanogels acted as potent drug carriers for hydrophobic anti-cancer drugs
and prolonged the drug release due to the chemical functionality of drug conjugation,
adsorption, porosity, and degradability [86]. In another study, the hypoxia-responsive
zwitterionic poly(phosphorylcholine)-based nanogel (HPMPC) was able to degrade rapidly
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in a hypoxic environment and led to the release of the loaded drug which then inhibited the
tumor both in vitro and in vivo [87]. More interestingly, the nanogels could pass through
the blood–brain barrier (BBB) without any external assistance, as the nanogels were able to
mimic the cell membrane of phosphorylcholine polymers leading to the accumulation of
nanogels at the desired site [88]. The promising nanogel carriers, harmine nanocrystals,
were generated by Huang et al. for nose-to-brain delivery of poorly soluble drugs [89]. The
study showed a 25-fold increase in bioavailability in the brain through the intranasal route
compared to the oral route [89]. A pH-triggered charge-reversible chitosan-polypyrrole
nanogel had a good cytocompatibility and excellent protein resistance, as well as a high
DOX loading efficiency. This self-adaptive charge-switching DOX-loaded nanogel exhib-
ited a prolonged blood circulation time, enhanced tumor acceleration, better penetration,
and a high uptake in tumor cells, making it an ideal candidate to deliver the chemother-
apeutic drugs [90]. Qu et al. [91] developed a prodrug nanogel made from methacrylic
acid (MAA), CPT monomer (CTPM), and N-N’-methylenebisacrylamide which was named
as P(CPT-MAA). This nanogel was a redox/pH dual-dependent nanogel, regulated by
concentrations of glutathione and pH, which inhibited tumors both in vitro and in vivo
under the desired conditions [91]. In another study, a supramolecular polymer nanogel was
used to deliver an anti-inflammatory drug, Dexamethasone, dermally. This drug was re-
leased from the nanogel via a host–guest molecular recognition [92]. A study demonstrated
that bovine serum albumin-gum arabic aldehyde (BSA-GAA) containing 5-fluorouracil
responded to the pH changes and the high level of drugs were released at lower pH and
inhibited the growth of MCF-7 breast cancer cells [93]. Other than drug delivery for cancer
therapy, vancomycin-loaded DNA nanogels were made to deliver antibiotics. This nanogel
showed a constant release of vancomycin over the course of 24 h, as well as synergistic
anti-inflammatory and antibacterial activities [94]. Table 1 summarizes the inhibitors and
drugs delivered by polysaccharide-based hydrogels DDSs.
Table 1. Summary of various drugs and inhibitors delivered by polysaccharide-based hydrogels DDSs.
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Table 1. Cont.
Polymer Name Polysaccharides and Additives DeliveredMolecule Functions of Polysaccharides Year References
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4. Factors Affecting the Efficacy of Hydrogel Drug Delivery Systems
4.1. Size of Nanoparticles
The size of polysaccharide-based NPs is particularly attractive to determine the ef-
ficiency of drug encapsulation and the release profile. In addition, the size of NPs is
predominantly essential to determine the ability of a drug nanocarrier to localize and
bind to the targeted cell membrane, and for the cellular interaction, including cellular
uptake, half-life, and biodistribution of the NPs to take place [95,96]. The molecular weight
of the polymer used for the formation of NPs can profoundly influence the size of the
synthesized NPs [97]. Karimi et al. demonstrated that the increased size of magnetic
chitosan NPs crosslinked with ҡ-carrageenan was observed by increasing the molecular
weight of chitosan [97]. The same study then reported the increased loading efficiency of
sunitinib following the increase of chitosan molecular weight and the size of NPs. However,
the release rate of sunitinib decreased due to the increased molecular weight of chitosan
and larger size of NPs [97]. In another study, Unsoy et al. reported the decreased size of
chitosan-coated magnetic NPs following the decreased amount of ammonium hydroxide
(NH4OH) used during the synthesis [98]. The same study also demonstrated the increased
release of loaded doxorubicin from the smaller size of chitosan-coated magnetic NPs. A
similar trend in findings was also reported in a study by Bruinsmann et al. [99]. Another
study by Tran et al. generated a smaller nanoplex of chitosan and curcumin through the mil-
ifluidic method and showed a higher supersaturation which improved the bioavailability
of the DDS compared to the larger nanoplex [100].
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4.2. Shape of Nanoparticles
Other than size, the shape geometry of NPs is also a factor that could affect the
pharmacokinetics and pharmacodynamics of drugs, the transport properties in fluids,
and the adhesion kinetics of the NPs to target cells [101]. While NPs were conventionally
synthesized in spherical shapes, recent NP engineering has enabled the generation of NPs
in different shapes including rods, prisms, cubes, stars, and disks [102]. Different methods
that could produce NPs in controlled shapes are lithography-based, membrane stretching,
and self-assembly methods [103]. In the study reported by Agarwal et al., asymmetrical
NPs were found to enhance the penetration and distribution of NPs in the solid tissues
and tumor. Interestingly, nanodiscs showed a higher accumulation in the tumor spheroids
compared to nanorods of similar size [104]. This suggested that NPs in different geometries
could interact with cell membranes differently and might exert different biological activities.
With the advent of nanotechnology, modifications can be made on native cellulose fibers to
manufacture nano-celluloses including cellulose nanowhiskers (CNWs), nanocrystals and
nanofibers [105–109]. The rod-like CNWs are believed to be a promising DDS owing to their
nano-dimensions, large surface area, hydrophilic properties, and high biocompatibility
and biodegradability [110].
4.3. Hydrogel Swelling Ratio
Hydrogels have the capacity to swell to hundreds or thousands of times their own
weight [111]. The swelling ratio is indicated by the amount of water absorbed and retained
the hydrogel matrix [112]. The ability of hydrogels to absorb water depends on the
composition of hydrophilic functional groups, the structure of the polymers, the interaction
between polymers and solvent, and the crosslinking degree [113]. The equilibrium swelling
ratio is reached when the balance occurs between the osmotic forces of the functional groups
and the restrictive forces of the higher ordering of the polymer [114,115]. The swelling
ratio is determined by the following equation [116]:






where ms and md are the mass of swollen and dried hydrogel samples, respectively.
The swelling ratio of hydrogel is closely related to its release kinetics which drastically
affect the diffusion of drugs [116]. As hydrogels are made of polymeric networks, drugs
can become entrapped in the polymer matrix complex or attached to the polymer either via
covalent bonding or physical attraction via a hydrogen bond, an ionic bond, or hydrophobic
interaction (Figure 5). These properties allow hydrogel to carry a concentrated amount
of drugs to their target site and release the drugs through diffusion, swelling, chemical
control, or stimuli [116].
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of an effective DDS that need to be accommodated for, include maintaining both struc-
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curately characterized. 
In addition to the general requirements, the methodology needs to be optimized to 
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5. Challenges in Hydrogel Drug Delivery System Development
While polysaccharides possess a large number of advantageous properties making
them suitable in the development of delivery systems for various types of drugs, they are
also associated with disadvantageous properties. For example, chitosan alone has low
solubility and is extremely pH sensitive, limiting the chemical modifications that can be
carried ou as well as the routes of administration that can be used. Both ral and mucosal
administrations are not ideal with chitosan as the pH sensitivity in acidic conditions results
in rapid degradation in the stomach, while the low solubility in water limits the desirable
mucoadhesive properties, resulting in poor absorption through mucosal sites [117]. Other
polysaccharides such as pectin and guar gum are also associated with limitations, such as
poor mechanical stability [118,119]. However, many of these limitations can be addressed
through surface modific n or incorporation of ot er molecules. Therefore, the major
limitations in the development of DDSs actually lie in the developmental stages, as many
factors and requirements need to be taken into consideration. The requirements of an
effective DDS that need to be accommodated for, include maintaining both structural
stability, the biological properties of the drug, and the polysaccharide; maintaining a
small size distribution; igh encapsulation efficiency and loading capacity; low levels of
aggregation; rele se profiles suitable for the i tended use, nd the display of no cytot xic
effects [120]. Furthermore, biodegradability, high biocompatibility, gel forming capacity,
high polysaccharide stability, and good swelling potential are also considered essential
for an effective hydrogel DDS [120]. For the development of an appropriate hydrogel
DDS with ideal biological properties, not only do all the different requirements need to be
identified, but they also need to be successf lly impl ment d in the synthesis process and
ccurately charact riz d.
In addition to the general requirements, the methodology needs to be optimized
to meet the ideal physicochemical properties of the DDS. Depending on the intended
use, which includes the nature of the therapeutic agent being encapsulated, the target
delivery site, the ideal hydrogel size, shape, degradation rate, and response to surrounding
stimuli, as well as bioavailability need to be achieved. Furthermore, due to th highly
variable molecular weights and surface chemistry of polysacchari es, the development of
polysaccharide-based DDS is more difficult than the development of synthetic polymer-
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based DDS [121]. One of the physiological properties that determines both DDS cellular
uptake and bioavailability is the size of the hydrogels [122]. While numerous methods have
been identified to optimize the production of nanogels with a desired size range, as well as
a uniform distribution of size, the propensity of polysaccharide-based nanogels to form
crosslinks when placed in aqueous solutions may lead to the formation of large aggregates,
especially at high polysaccharide concentration [24,73,123]. On top of that, the choice
of method used may also serve as a major challenge, as each method is associated with
its own advantages and limitations, and determines DDS properties such as shape, size
distribution, porosity, and drug encapsulation efficiency [120]. In addition to identifying
the ideal method based on the desired properties for the specific application, the methods
that can be used also depend on properties of the drug, including solubility and surface
properties, as well as the polysaccharide of choice, site of delivery, and biological activities.
The release of the kinetics of drugs from the delivery system can often be difficult to
predict, especially for stimuli-responsive hydrogels, and are dependent on the degradation
rate and swelling rate, both of which are influenced by both external factors and intrinsic
delivery system properties [124,125]. Many researchers rely on the use of computational
models such as zero-order kinetics, first-order kinetics, and Peppa’s model to predict
the release of drugs from hydrogel DDSs. While these models may be accurate in some
delivery systems, it is difficult to predict the release of drugs from unique and complex
hydrogels as this is highly influenced by environmental factors such as pH, temperature,
and the presence of chemicals, as well as the presence of hydrophobic or hydrophilic
groups, the swelling capacity of the polysaccharide, and method of crosslinking used. In
addition to computational models, due to the high cost of drugs, many researchers rely
on model proteins or drugs such as BSA or dyes to predict release. While this allows
the study to be more cost-effective, it may not always accurately represent or translate
the in vitro findings to medicinal applications [126]. Additionally, even when accurately
characterized during synthesis, hydrogel DDSs are prone to surface changes in response to
external physiological stimuli, making the release pattern difficult to predict [120]. Other
than release, the bioavailability of polysaccharide-based hydrogels may also be difficult to
predict. In order to ensure the drug is released at the target site, the premature clearance of
the DDS needs to be prevented [55]. Furthermore, the release time also needs to be taken
into consideration when designing hydrogels to ensure sufficient time for drug release and
accumulation prior to hydrogel clearance. From the various properties and limiting factors
of DDS development it can be seen that the requirement to fine-tune methodology in order
to achieve the desired properties is a major limitation associated with polysaccharide-based
hydrogel DDSs.
6. Conclusions
The use of polysaccharides could enhance the targeted and controlled delivery of
drugs to the target site due to their advantageous properties. These include high biocom-
patibility and biodegradability, easy availability, cost-effectiveness, and easy modification
for overcoming limitations. Additionally, the presence of free functional groups such as
carboxyl, amino, and hydroxyl groups allows for the chemical modification and drug
conjugation. Polysaccharide-based hydrogels have been identified as having tunable
physicochemical properties that make them ideal as drug carriers. Furthermore, due to
their low immunogenicity, excellent biocompatibility, and biodegradation, they have been
used for the development of in situ-forming, macroporous, and shear-thinning hydrogels.
They can be used as hydrogel-forming microneedles for the delivery of accurate drug
doses via transdermal administration and minimally invasive injections. The identification
of such novel drug carriers potentially serves as a step towards more accurate dosing
for sustainable treatments while also minimizing drug-associated cytotoxicity. There is
a great amount of recent research carried out on the potential applications of various
polysaccharide-based hydrogels, resulting in the identification of novel methodologies for
the development of improved DDSs. However, the numerous requirements that need to be
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met for a DDS to be effective, as well as the factors that contribute towards its properties
all need to be taken into consideration. This may serve as a potential challenge in the
development of new DDS, as well as in the process of manufacturing DDSs on a large scale.
Future research on micro/nanogel formation from natural polymers should have more
research on the long-term cytotoxicity as well as an improvement of stability and control
for in vivo applications.
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13. Akbal, Ö.; Erdal, E.; Vural, T.; Kavaz, D.; Denkbaş, E.B. Comparison of protein-and polysaccharide-based nanoparticles for cancer
therapy: Synthesis, characterization, drug release, and interaction with a breast cancer cell line. Artif. Cell Nanomed. B 2017, 45,
193–203. [CrossRef]
14. Neerooa, B.N.H.M.; Ooi, L.-T.; Shameli, K.; Dahlan, N.A.; Islam, J.M.M.; Pushpamalar, J.; Teow, S.-Y. Development of polymer-
assisted nanoparticles and nanogels for cancer therapy: An update. Gels 2021, 7, 60. [CrossRef] [PubMed]
15. Sharma, P. Microparticles drug delivery system: A review. World J. Pharm. Pharm. Sci. 2016, 5, 543–566.
16. Abdo, G.G.; Zagho, M.M.; Khalil, A. Recent advances in stimuli-responsive drug release and targeting concepts using mesoporous
silica nanoparticles. Emergent Mater. 2020, 3, 407–425. [CrossRef]
17. Sood, A.; Gupta, A.; Agrawal, G. Recent advances in polysaccharides based biomaterials for drug delivery and tissue engineering
applications. Carbohydr. Polym. Technol. App. 2021, 2, 100067.
18. Lima, C.S.A.; Balogh, T.S.; Varca, J.P.R.O.; Varca, G.H.C.; Lugão, A.B.; Camacho-Cruz, L.A.; Bucio, E.; Kadlubowski, S.S.
An updated review of macro, micro, and nanostructured hydrogels for biomedical and pharmaceutical applications. Pharmaceutics
2020, 12, 970. [CrossRef]
19. Moghaddam, R.H.; Dadfarnia, S.; Shabani, A.M.H.; Moghaddam, Z.H.; Tavakol, M. Electron beam irradiation synthesis of porous
and non-porous pectin based hydrogels for a tetracycline drug delivery system. Mater. Sci. Eng. C 2019, 102, 391–404. [CrossRef]
Gels 2021, 7, 153 18 of 22
20. Yegappan, R.; Selvaprithiviraj, V.; Amirthalingam, S.; Jayakumar, R. Carrageenan based hydrogels for drug delivery, tissue
engineering and wound healing. Carbohydr. Polym. 2018, 198, 385–400. [CrossRef]
21. Suner, S.S.; Sahiner, M.; Sengel, S.B.; Rees, D.J.; Reed, W.F.; Sahiner, N. 17-Responsive biopolymer-based microgels/nanogels
for drug delivery applications. In Stimuli Responsive Polymeric Nanocarriers for Drug Delivery Applications; Makhlouf, A.S.H.,
Abu-Thabit, N.Y., Eds.; Woodhead Publishing: Sawston, UK, 2018; Volume 1.
22. Mauri, E.; Giannitelli, S.M.; Trombetta, M.; Rainer, A. Synthesis of nanogels: Current trends and future outlook. Gels 2021, 7, 36.
[CrossRef]
23. Seyfoori, A.; Koshkaki, M.R.; Majidzadeh-A, K. 26-Nanohybrid stimuli-responsive microgels: A new approach in cancer therapy.
In Nanoarchitectonics for Smart Delivery and Drug Targeting; Holban, A.M., Grumezescu, A.M., Eds.; William Andrew Publishing:
New York, NY, USA, 2016; pp. 715–742.
24. Zhang, X.; Malhotra, S.; Molina, M.; Haag, R. Micro- and nanogels with labile crosslinks–from synthesis to biomedical applications.
Chem. Soc. Rev. 2015, 44, 1948–1973. [CrossRef]
25. Dimatteo, R.; Darling, N.J.; Segura, T. In situ forming injectable hydrogels for drug delivery and wound repair. Adv. Drug Deliv.
Rev. 2018, 127, 167–184. [CrossRef] [PubMed]
26. Thambi, T.; Li, Y.; Lee, D.S. Injectable hydrogels for sustained release of therapeutic agents. J. Control. Release 2017, 267, 57–66.
[CrossRef] [PubMed]
27. Yin, N.; Guo, X.; Sun, R.; Liu, H.; Tang, L.; Gou, J.; Yin, T.; He, H.; Zhang, Y.; Tang, X. Intra-articular injection of indomethacin–
methotrexate in situ hydrogel for the synergistic treatment of rheumatoid arthritis. J. Mater. Chem. B 2020, 8, 993–1007. [CrossRef]
28. Hoang, H.T.; Jo, S.-H.; Phan, Q.-T.; Park, H.; Park, S.-H.; Oh, C.-W.; Lim, K.T. Dual pH-/thermo-responsive chitosan-based
hydrogels prepared using “click” chemistry for colon-targeted drug delivery applications. Carbohydr. Polym. 2021, 260, 117812.
[CrossRef] [PubMed]
29. Song, Y.; Nagai, N.; Saijo, S.; Kaji, H.; Nishizawa, M.; Abe, T. In situ formation of injectable chitosan-gelatin hydrogels through
double crosslinking for sustained intraocular drug delivery. Mater. Sci. Eng. C 2018, 88, 1–12. [CrossRef] [PubMed]
30. Ding, H.; Li, B.; Jiang, Y.; Liu, G.; Pu, S.; Feng, Y.; Jia, D.; Zhou, Y. pH-responsive UV crosslinkable chitosan hydrogel via
“thiol-ene” click chemistry for active modulating opposite drug release behaviors. Carbohydr. Polym. 2021, 251, 117101. [CrossRef]
[PubMed]
31. De France, K.J.; Xu, F.; Hoare, T. Structured Macroporous Hydrogels: Progress, Challenges, and Opportunities. Adv. Healthc.
Mater. 2018, 7, 1700927. [CrossRef] [PubMed]
32. Lee, S.S.; Santschi, M.; Ferguson, S.J. A Biomimetic Macroporous Hybrid Scaffold with Sustained Drug Delivery for Enhanced
Bone Regeneration. Biomacromolecules 2021, 22, 2460–2471. [CrossRef]
33. Zhang, X.; Li, Y.; He, D.; Ma, Z.; Liu, K.; Xue, K.; Li, H. An effective strategy for preparing macroporous and self-healing bioactive
hydrogels for cell delivery and wound healing. Chem. Eng. Sci. 2021, 425, 130677. [CrossRef]
34. Goel, S.; Kaur, T.; Singh, N.; Jacob, J. Tunable macroporous D-galactose based hydrogels for controlled release of a hydrophilic
drug. Eur. Polym. J. 2021, 150, 110409. [CrossRef]
35. Ehsanipour, A.; Nguyen, T.; Aboufadel, T.; Sathialingam, M.; Cox, P.; Xiao, W.; Walthers, C.M.; Seidlits, S.K. Injectable, hyaluronic
acid-based scaffolds with macroporous architecture for gene delivery. Cell Mol. Bioeng. 2019, 12, 399–413. [CrossRef] [PubMed]
36. Hou, S.; Lake, R.; Park, S.; Edwards, S.; Jones, C.; Jeong, K.J. Injectable macroporous hydrogel formed by enzymatic cross-linking
of gelatin microgels. ACS Appl. Bio. Mater. 2018, 1, 1430–1439. [CrossRef]
37. Wang, L.; Deng, F.; Wang, W.; Li, A.; Lu, C.; Chen, H.; Wu, G.; Nan, K.; Li, L. Construction of injectable self-healing macroporous
hydrogels via a template-free method for tissue engineering and drug delivery. ACS Appl. Mater. Interfaces 2018, 10, 36721–36732.
[CrossRef] [PubMed]
38. Chen, M.H.; Wang, L.L.; Chung, J.J.; Kim, Y.-H.; Atluri, P.; Burdick, J.A. Methods to assess shear-thinning hydrogels for application
as injectable biomaterials. ACS Biomater. Sci. Eng. 2017, 3, 3146–3160. [CrossRef] [PubMed]
39. Prasad, N.K.; Shome, R.; Biswas, G.; Ghosh, S.S.; Dalal, A. Discerning the self-healing, shear-thinning characteristics and
therapeutic efficacy of hydrogel drug carriers migrating through constricted microchannel resembling blood microcapillary.
Colloids Surf. A Physiochem. Eng. Asp. 2021, 626, 127070. [CrossRef]
40. Gharaie, S.; Dabiri, S.M.H.; Akbari, M. Smart shear-thinning hydrogels as injectable drug delivery systems. Polymers 2018,
10, 1317. [CrossRef] [PubMed]
41. Wang, Q.; Newby, B.-M.Z. Layer-by-layer polyelectrolyte coating of alginate microgels for sustained release of sodium benzoate
and zosteric acid. J. Drug Deliv. Sci. Technol. 2018, 46, 46–54. [CrossRef]
42. Khan, A.; Othman, M.B.H.; Chang, B.P.; Akil, H.M. Preparation, physicochemical and stability studies of chitosan-PNIPAM based
responsive microgels under various pH and temperature conditions. Iran. Polym. J. 2015, 24, 317–328. [CrossRef]
43. Oh, J.K.; Lee, D.I.; Park, J.M. Biopolymer-based microgels/nanogels for drug delivery applications. Prog. Polym. Sci. 2009, 34,
1261–1282. [CrossRef]
44. Holban, A.M.; Grumezescu, A.M. Nanoarchitectonics for Smart Delivery and Drug Targeting; William Andrew Publishing: New York,
NY, USA, 2016.
45. Nakai, T.; Hirakura, T.; Sakurai, Y.; Shimoboji, T.; Ishigai, M.; Akiyoshi, K. Injectable hydrogel for sustained protein release by
salt-induced association of hyaluronic acid nanogel. Macromol. Biosci. 2012, 12, 475–483. [CrossRef]
Gels 2021, 7, 153 19 of 22
46. Jamard, M.; Hoare, T.; Sheardown, H. Nanogels of methylcellulose hydrophobized with N-tert-butylacrylamide for ocular drug
delivery. Drug Deliv. Transl. Res. 2016, 6, 648–659. [CrossRef] [PubMed]
47. Zhou, K.; Wang, X.; Chen, D.; Yuan, Y.; Wang, S.; Li, C.; Yan, Y.; Liu, Q.; Shao, L.; Huang, L.; et al. Enhanced treatment effects of
Tilmicosin against Staphylococcus aureus cow mastitis by self-assembly sodium alginate-chitosan nanogel. Pharmaceutics 2019,
11, 524. [CrossRef] [PubMed]
48. Wang, K.; Lin, S.; Nune, K.C.; Misra, R.D.K. Chitosan-gelatin-based microgel for sustained drug delivery. J. Biomater. Sci. Polym.
Ed. 2016, 27, 441–453. [CrossRef]
49. Klinger, D.; Landfester, K. Stimuli-responsive microgels for the loading and release of functional compounds: Fundamental
concepts and applications. Polymer 2012, 53, 5209–5231. [CrossRef]
50. Su, H.; Jia, Q.; Shan, S. Synthesis and characterization of Schiff base contained dextran microgels in water-in-oil inverse
microemulsion. Carbohydr. Polym. 2016, 152, 156–162. [CrossRef]
51. Zhang, B.; Wei, B.; Hu, X.; Jin, Z.; Xu, X.; Tian, Y. Preparation and characterization of carboxymethyl starch microgel with different
crosslinking densities. Carbohydr. Polym. 2015, 124, 245–253. [CrossRef]
52. Mejías, J.C.; Roy, K. In-vitro and in-vivo characterization of a multi-stage enzyme-responsive nanoparticle-in-microgel pulmonary
drug delivery system. J. Control. Release 2019, 316, 393–403. [CrossRef] [PubMed]
53. Mahmoudi, Z.; Mohammadnejad, J.; Razavi Bazaz, S.; Abouei Mehrizi, A.; Saidijam, M.; Dinarvand, R.; Ebrahimi Warkiani, M.;
Soleimani, M. Promoted chondrogenesis of hMCSs with controlled release of TGF-β3 via microfluidics synthesized alginate
nanogels. Carbohydr. Polym. 2020, 229, 115551. [CrossRef] [PubMed]
54. Mahinroosta, M.; Jomeh Farsangi, Z.; Allahverdi, A.; Shakoori, Z. Hydrogels as intelligent materials: A brief review of synthesis,
properties and applications. Mater. Today Chem. 2018, 8, 42–55. [CrossRef]
55. Alexis, F.; Pridgen, E.; Molnar, L.K.; Farokhzad, O.C. Factors affecting the clearance and biodistribution of polymeric nanoparticles.
Mol. Pharm. 2008, 5, 505–515. [CrossRef]
56. Deng, L.; Li, Q.; Al-Rehili, S.; Omar, H.; Almalik, A.; Alshamsan, A.; Zhang, J.; Khashab, N.M. Hybrid iron oxide–graphene
oxide–polysaccharides microcapsule: A micro-matryoshka for on-demand drug release and antitumor therapy in vivo. ACS Appl.
Mater. Interfaces 2016, 8, 6859–6868. [CrossRef] [PubMed]
57. Yurkshtovich, T.; Golub, N.; Yurkshtovich, N.; Bychkovskii, P.; Kosterova, R.; Alinovskaya, V. Starch phosphate microgels for
controlled release of biomacromolecules. Appl. Biochem. Microbiol. 2017, 53, 814–822. [CrossRef]
58. Zhang, Y.; Wang, F.; Li, M.; Yu, Z.; Qi, R.; Ding, J.; Zhang, Z.; Chen, X. Self-stabilized hyaluronate nanogel for intracellular
codelivery of Doxorubicin and Cisplatin to osteosarcoma. Adv. Sci. 2018, 5, 1700821. [CrossRef]
59. Soni, G.; Yadav, K.S. Nanogels as potential nanomedicine carrier for treatment of cancer: A mini review of the state of the art.
Saudi. Pharm. J. 2016, 24, 133–139. [CrossRef] [PubMed]
60. Sawada, S.-I.; Yukawa, H.; Takeda, S.; Sasaki, Y.; Akiyoshi, K. Self-assembled nanogel of cholesterol-bearing xyloglucan as a drug
delivery nanocarrier. J. Biomater. Sci. Polym. Ed. 2017, 28, 1183–1198. [CrossRef]
61. Wang, J.; Zhao, W.; Chen, H.; Qin, A.; Zhu, P. Anti-tumor study of chondroitin sulfate-methotrexate nanogels. Nanoscale Res. Lett.
2017, 12, 572. [CrossRef]
62. Fiorica, C.; Mauro, N.; Pitarresi, G.; Scialabba, C.; Palumbo, F.S.; Giammona, G. Double-network-structured graphene oxide-
containing nanogels as photothermal agents for the treatment of colorectal cancer. Biomacromolecules 2017, 18, 1010–1018.
[CrossRef]
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